Sandoz's Biosimilar Pipeline Offers Hope Despite Sales Miss -- Market Talk

Dow Jones

2025/04/30

0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 30, 2025 01:46 ET (05:46 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531776283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531776283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531776283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531776283","market":"nz","top_or_hot":-1,"title":"Sandoz's Biosimilar Pipeline Offers Hope Despite Sales Miss -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2025 01:46 ET (05:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sandoz's Biosimilar Pipeline Offers Hope Despite Sales Miss -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSandoz's Biosimilar Pipeline Offers Hope Despite Sales Miss -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-30 13:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2025 01:46 ET (05:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOPE","symbol_name":"Hope Bancorp, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531776283","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531776283","pubTimestamp":1745991960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HOPE":"Hope Bancorp, Inc."},"translate_title":"尽管销售不佳，山德士的生物仿制药管道仍带来希望——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOPE":1},"content_text":"0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 01:46 ET (05:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}